- Conditions
- Healthy
- Interventions
- TT-01025-CL
- Drug
- Lead sponsor
- LG Chem
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 64 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Las Vegas, Nevada
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–14
of 14
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Gout, Hyperuricemia
- Interventions
- Xanthine Oxidase Inhibitor, nonsteroidal anti-inflammatory drug
- Drug
- Lead sponsor
- LG Chem
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Gout, Hyperuricemia
- Interventions
- LC350189 Tablet, LC350189 Capsule
- Drug
- Lead sponsor
- LG Chem
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Las Vegas, Nevada
- Conditions
- Non-small Cell Lung Cancer(NSCLC), Head and Neck Squamous Cell Carcinoma(HNSCC), Renal Cell Carcinoma(RCC), Urothelial Carcinoma, Malignant Melanoma
- Interventions
- Phase 1a: LB-LR1109, Phase 1b: LB-LR1109 and Atezolizumab
- Drug
- Lead sponsor
- LG Chem
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Fairfax, Virginia
- Conditions
- Gout, Hyperuricemia, Gout Flare, Tophi
- Interventions
- Tigulixostat, Placebo
- Drug
- Lead sponsor
- LG Chem
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 354 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 36
- States / cities
- Birmingham, Alabama • Covina, California • Clearwater, Florida + 31 more
- Conditions
- Gout, Hyperuricemia
- Interventions
- Xanthine Oxidase Inhibitor
- Drug
- Lead sponsor
- LG Chem
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Obese, Overweight, Healthy
- Interventions
- LB64640, Placebo
- Drug
- Lead sponsor
- LG Chem
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 112 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Chula Vista, California
- Conditions
- Healthy, Diabetes Mellitus, Type 2
- Interventions
- LC542019, Placebo
- Drug
- Lead sponsor
- LG Chem
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Las Vegas, Nevada
- Conditions
- Gout, Hyperuricemia, Gout Flare, Tophi
- Interventions
- Tigulixostat, Allopurinol, Placebo
- Drug
- Lead sponsor
- LG Chem
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 2,202 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 124
- States / cities
- Birmingham, Alabama • Daphne, Alabama • Mobile, Alabama + 91 more
- Conditions
- Gout, Hyperuricemia
- Interventions
- LC350189 formulated capsule, Placebo
- Drug
- Lead sponsor
- LG Chem
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 156 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 34
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Mesa, Arizona + 28 more
- Conditions
- Gout, Hyperuricemia
- Interventions
- Tigulixostat, Theophylline
- Drug
- Lead sponsor
- LG Chem
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Gout, Hyperuricemia
- Interventions
- [14C] LC350189
- Drug
- Lead sponsor
- LG Chem
- Industry
- Eligibility
- 18 Years to 55 Years · Male only
- Enrollment
- 6 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Hyperuricemia, Gout, Qt Interval, Variation in
- Interventions
- LC350189 200mg, Placebo, Moxifloxacin 400mg, LC350189 600mg
- Drug
- Lead sponsor
- LG Chem
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 37 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Gout, Hyperuricemia
- Interventions
- LC350189 200 mg
- Drug
- Lead sponsor
- LG Chem
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 37 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Orlando, Florida